Visual field constriction in 91 Finnish children treated with vigabatrin

Sampsa Vanhatalo1, Iiris Nousiainen, Kai Eriksson

  • 1Unit of Child Neurology, Hospital for Children and Adolescents, University Hospital of Helsinki, Finland. sampsa.vanhatalo@helsinki.fi

Epilepsia
|July 10, 2002
PubMed

Insights

Vigabatrin (VGB) can cause visual field constrictions (VFCs) in children. Higher VGB doses and longer treatment durations correlate with VFCs, suggesting a potential link to cumulative exposure.

Area of Science:

  • Pediatric Neurology
  • Ophthalmology
  • Pharmacology

Background:

  • Vigabatrin (VGB) is an antiepileptic drug used in children.
  • Visual field constrictions (VFCs) are a known potential side effect of VGB treatment.
  • Understanding VFC prevalence and features in pediatric populations is crucial for patient safety.

Purpose of the Study:

  • To investigate the prevalence and characteristics of VFCs in children treated with VGB.
  • To identify factors associated with the development of VFCs in this pediatric cohort.

Main Methods:

  • Systematic collection of children with VGB treatment history across 15 Finnish neuropediatric units.
  • Inclusion of 91 children (ages 5.6-17.9) who could reliably perform Goldmann kinetic perimetry.
  • Definition of abnormal VFC as visual field extent <70 degrees in the temporal meridian.

Main Results:

  • VFCs (<70 degrees) were detected in 18.7% (17/91) of children in repeated tests.
  • Children with VFCs had received higher total VGB doses compared to those without.
  • Statistically significant inverse correlations were found between temporal visual field extent and total VGB dose/treatment duration.

Conclusions:

  • Prevalence of VFCs in children is influenced by the definition of normality due to test variability.
  • VFCs can occur in children treated with VGB, with higher cumulative doses potentially increasing risk.
  • Critical reevaluation of suspected VFCs is needed to prevent misdiagnosis; prevalence may be lower than in adults.
Abstract

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...